The EPO published patent application EP3864018A1 for Novartis AG covering solid forms of a triazolo-pyrimidine derivative compound with potential pharmaceutical applications. The application lists eight inventors and received an A1 publication kind code indicating it includes the search report. The patent designates all major European states including Germany, France, UK, Italy, Spain, and others.

Pharmaceutical companies and drug manufacturers should review this patent publication for freedom-to-operate considerations if developing similar compounds. Patent publications do not create immediate compliance obligations but establish filing dates for priority claims. Companies with overlapping research programs may need to evaluate potential licensing needs or design-around strategies.